Q3 2019 EPS Estimates for Joint Corp Lowered by DA Davidson (NASDAQ:JYNT)
Joint Corp (NASDAQ:JYNT) – Research analysts at DA Davidson lowered their Q3 2019 earnings estimates for shares of Joint in a report released on Friday, August 9th. DA Davidson analyst M. Kawamoto now forecasts that the company will post earnings per share of $0.03 for the quarter, down from their prior estimate of $0.04. DA Davidson currently has a “Buy” rating and a $21.00 target price on the stock.
Joint (NASDAQ:JYNT) last released its earnings results on Thursday, August 8th. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.01. Joint had a net margin of 5.38% and a return on equity of 127.07%. The business had revenue of $11.17 million during the quarter, compared to analysts’ expectations of $11.08 million.
NASDAQ:JYNT opened at $18.26 on Monday. Joint has a 1-year low of $6.51 and a 1-year high of $21.80. The company has a quick ratio of 1.00, a current ratio of 1.00 and a debt-to-equity ratio of 4.38. The firm has a fifty day moving average price of $19.00. The company has a market capitalization of $251.58 million, a PE ratio of 456.50, a PEG ratio of 8.98 and a beta of 0.97.
In other Joint news, Director James H. Amos, Jr. purchased 4,000 shares of the business’s stock in a transaction on Wednesday, June 5th. The stock was acquired at an average price of $16.08 per share, with a total value of $64,320.00. Following the acquisition, the director now directly owns 80,497 shares of the company’s stock, valued at approximately $1,294,391.76. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Ronald V. Davella sold 10,190 shares of the firm’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $16.46, for a total value of $167,727.40. Following the sale, the director now directly owns 15,457 shares of the company’s stock, valued at approximately $254,422.22. The disclosure for this sale can be found here. Company insiders own 6.10% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. Bandera Partners LLC lifted its holdings in Joint by 4.6% during the 2nd quarter. Bandera Partners LLC now owns 1,364,301 shares of the company’s stock valued at $24,830,000 after purchasing an additional 60,000 shares during the last quarter. BlackRock Inc. lifted its holdings in Joint by 1,224.0% during the 2nd quarter. BlackRock Inc. now owns 769,378 shares of the company’s stock valued at $14,002,000 after purchasing an additional 711,267 shares during the last quarter. Skylands Capital LLC lifted its holdings in Joint by 4.4% during the 2nd quarter. Skylands Capital LLC now owns 550,701 shares of the company’s stock valued at $10,023,000 after purchasing an additional 23,051 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Joint by 17.3% during the 2nd quarter. Acadian Asset Management LLC now owns 254,919 shares of the company’s stock valued at $4,639,000 after purchasing an additional 37,653 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in Joint by 448.3% during the 2nd quarter. Allianz Asset Management GmbH now owns 231,097 shares of the company’s stock valued at $4,206,000 after purchasing an additional 188,952 shares during the last quarter. 47.69% of the stock is owned by institutional investors and hedge funds.
The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of March 07, 2019, the company operated 450 clinics in the United States.
Read More: Insider Trading – What You Need to Know
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.